Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18564070 | 0.84 | POLB (0.52) | NQO2CYP1A2POLBMPOKDM4E | |
| SCHEMBL25156298 | 0.79 | NPSR1 (0.44) | NQO2POLBMPORAB9AKDM4E | |
| SCHEMBL23619772 | 0.76 | NQO2 (0.44) | NQO2POLBMPORAB9A | |
| SCHEMBL25544348 | 0.76 | CYP1A2 (0.50) | NQO2CYP1A2POLBKDM4ELMNA | |
| SCHEMBL23619770 | 0.76 | NQO2 (0.42) | NQO2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL11808986 | 0.73 | PRNP (0.39) | NQO2CYP1A2MPOLMNAALDH1A1 | |
| SCHEMBL2223768 | 0.73 | BACE1 (0.60) | CYP1A2POLBCCR1ALDH1A1 | |
| SCHEMBL29923580 | 0.73 | BACE1 (0.60) | CYP1A2POLBCCR1ALDH1A1 | |
| SCHEMBL2222111 | 0.72 | CYP1A2 (0.61) | CYP1A2POLBCCR1RAB9ACCR5 | |
| SCHEMBL30390874 | 0.72 | CYP1A2 (0.61) | CYP1A2POLBCCR1RAB9ACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079724-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| EP-2903612-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC INHIBITORS | INST NAT SANTE RECH MED (FR) | 2019-07-10 | — | — | EP | disclosed |
| US-10093627-B2 | Tetrahydroquinoline derivatives and their use as Epac inhibitors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-10-09 | — | — | US | disclosed |
| US-20180009757-A1 | Tetrahydroquinoline Derivatives and Their Use as Epac Inhibitors | Universite Paris-Saclay (FR) | 2018-01-11 | — | — | US | disclosed |
| US-9751838-B2 | Tetrahydroquinoline derivatives and their use as Epac inhibitors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-09-05 | — | — | US | disclosed |
| US-20150252002-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC INHIBITORS | Universite Paris-Saclay (FR) | 2015-09-10 | — | — | US | disclosed |
| EP-2903612-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC INHIBITORS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093627-B2 | Tetrahydroquinoline derivatives and their use as Epac inhibitors | EPAS1, RAPGEF3, PRKCQ | NQO2 944/4885CYP1A2 1878/4885POLB 3903/4885 |
| US-20180009757-A1 | Tetrahydroquinoline Derivatives and Their Use as Epac Inhibitors | EPAS1, RAPGEF3, PRKCQ | NQO2 944/4885CYP1A2 1878/4885POLB 3903/4885 |
| US-20150252002-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC INHIBITORS | EPAS1, RAPGEF3, PRKCQ | NQO2 944/4885CYP1A2 1878/4885POLB 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.